生物活性

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively。

体外研究

SRT1720抗最近的乙酰化酶同系物SIRT2 (EC1.5为37 μM)和SIRT3 (EC1.5 > 300 μM)的最大激活率达781%。SRT1720在氨基末端催化区的变构位点结合到SIRT1酶-肽底物复合物上，降低乙酰化底物的米氏常数值。用SRT1720处理一周后，饲喂的葡萄糖水平降低，处理三周后，饲喂的葡萄糖水平进一步降低，持续处理10周。SRT1720对用无糖食物喂养的鼠没有作用效果，显示出药理学SIRT1的激活不会产生低血糖。用SRT1720处理4周，明显降低高胰岛素血症，使升高的胰岛素水平恢部分复正常SRT1720处理腓肠肌，通过测定柠檬酸合酶活性发现线粒体各项能力上升15%。^[1]高浓度 SRT1720 (15 μM)诱导正常细胞活力轻微下降，约10-20%。SRT1720明显抑制VEGF依赖的 MM 细胞迁移

体内研究

SRT1720 exhibited a pharmacokinetic profile suitable for in vivo evaluation in both mouse (bioavailability = 50%, terminal t1/2 = ~5 h, Area Under the Curve (AUC) = 7,892 ng h/ml/) and rat (bioavailability = 25%, terminal t1/2 = ~8.4 h, AUC = 3,714 ng/h/ml). In DIO mice, fasting blood glucose levels are elevated (120–150 mg dl?1 range) after being placed on a high-fat diet. Administration of SRT1720 reduced fed glucose levels after 1 week of treatment with further reduction after 3 weeks of treatment that continued through 10 weeks of dosing. Glucose excursion during an intraperitoneal glucose tolerance test was also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 attenuated stress-induced premature cellular senescence and protected against emphysema induced by cigarette smoke and elastase in mice. In animal tumour model studies, SRT1720 inhibited MM tumour growth. SRT1720 enhanced the cytotoxic activity of bortezomib or dexamethasone

激酶实验

细胞实验

Cell viability was assessed with a colorimetric assay using MTT as described previously. Apoptosis assay was quantified using Annexin V-FITC/Propidium iodide (PI) apoptosis detection kit, as per manufacturer's instructions, followed by analysis on FACS Calibur

动物实验

Sirtinol (2 mg/kg) was administered by peritoneal injection, whereas SRT1720 (100 mg/kg) was administered through oral gavage 1 hour prior to CS exposure daily for 3 days. In a separate experiment, SRT1720 (25, 50, and 100 mg/kg) or PHA-408 (50 mg/kg) was dissolved in 0.5% carboxymethylcellulose containing 0.025% Tween 20 and injected via oral gavage into the conscious mice 24 hours prior to elastase administration, which was repeated daily (5 days per week) until 21 days after elastase administration. To study the therapeutic effect on emphysema, SRT1720 (100 mg/kg) was orally administered daily for 2 weeks after the development of elastase-induced emphysema

不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

参考文献

1.Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes 2007 Nov 29;450(7170):712-6. doi: 10.1038/nature06261.
2.Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells 2011 Dec;155(5):588-98. doi: 10.1111/j.1365-2141.2011.08888.x. Epub 2011 Sep 26.

体内溶解度

Clinical Trial Information ( data from http://clinicaltrials.gov )

注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

相关化合物库

使用AMQUAR产品发表文献后请联系我们